Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLX research report →
Price Chart
About the company
Bladex, Inc. (formerly Banco Latinoamericano de Comercio Exterior, S. A.
- CEO
- Jorge L. Salas
- IPO
- 1992
- Employees
- 175
- HQ
- Panama City, PN, PA
Get TickerSpark's AI analysis on BLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.48B
- P/E
- 8.00
- Fwd P/E
- 7.51
- PEG
- 9.62
- P/S
- 2.34
- P/B
- 1.02
- EV/EBITDA
- 15.44
- Div Yield
- 5.67%
- Gross Margin
- 53.99%
- Op Margin
- 38.36%
- Net Margin
- 38.36%
- ROE
- 13.96%
- ROIC
- 2.96%
Latest fiscal year · YoY change
- Revenue
- $339.60M-58.1%
- Gross Profit
- $317.50M+11.5%
- Op Income
- $226.90M
- Net Income
- $226.90M+10.2%
- EPS
- $6.11+9.1%
- OCF Growth
- +133.1%
- FCF Growth
- +132.8%
- Beta
- 0.82
- RSI (14)
- 34
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bladex delivered a record quarter driven by a larger commercial portfolio, strong net interest income, and resilient credit quality, while warning that NIM will likely ease modestly in Q4.· October 27, 2026
- Commercial portfolio hit a record $15 billion, up 15% sequentially and 38% year over year; even excluding the Panama sovereign loan, loans grew 7% sequentially and 29% year over year.
- Net interest income reached a record $79.8 million, up 9% from Q2 and 18% year over year; net interest margin was 2.30%.
- Net income was $63.2 million, up 15% year over year, with adjusted ROE at 15% and Tier 1 capital at 16.2%.
- Asset quality improved: stage 2 exposure fell to $82 million, or 0.5% of the portfolio, and no new exposure migrated to impaired status.
- Management kept full-year guidance largely intact, but expects the Panama loan to temporarily dilute Q4 NIM while boosting absolute NII; efficiency ratio should be around 27% and adjusted ROE 14%-15%.
Bladex reported Q3 2026 net income of $63.2 million, up 15% year over year, with adjusted ROE of 15% and return on average assets of 1.8%. Revenue reached $99.1 million, nearly 20% higher than a year ago; net interest income was a record $79.8 million, up 18% year over year, and net interest margin was 2.30%, six basis points above Q2. Non-interest income was $19.3 million, up 26% year over year, while operating expenses were $26.6 million and the efficiency ratio was 25.8%. The commercial portfolio ended at a record $15 billion, up 15% sequentially and 38% year over year; loans were $12.3 billion, up 18% sequentially and 41% year over year; deposits were $7.9 billion, up 16% year over year; stage 2 exposure declined to $82 million from $162 million; provisions were $10.4 million versus $8.6 million in Q2; and Tier 1 capital ended at 16.2%. For the full year, management expects commercial portfolio growth of around 35% (or around 25% excluding the Panama transaction), average deposit growth of around 20%, net interest margin around 2.25% after roughly 5 bps of compression, an efficiency ratio around 27%, adjusted ROE of 14%-15%, and Tier 1 of 15%-16%.
Jorge Salas framed the quarter as evidence that Bladex is executing well across its core growth pillars: commercial lending, fee income, and transactional services. He emphasized that the business grew without relaxing underwriting standards and that the Panama sovereign loan showcased scale, funding flexibility, and capital efficiency rather than a push to maximize margin. His tone was upbeat but measured, repeatedly noting that strong current momentum is not expected to fully repeat and that the company will keep a conservative approach to risk and growth.
Annette van Hoorde de Solís highlighted the mechanics behind the quarter’s results: record NII of $79.8 million, NIM of 2.30%, a 15% year-over-year rise in net income, and a 16.2% Tier 1 ratio. She said the quarter benefited from higher average loan balances, improved funding spreads, efficient liquidity management, and accelerated recognition of deferred fees from prepayments, while also noting that underlying lending spreads remain under pressure. On credit, she cited stage 2 exposure falling to $82 million, stage 3 stable at $75 million, and reserve coverage on impaired credits rising to 1.4x; on funding, she noted deposits at $7.9 billion, nearly $2 billion in liquid assets, and about $450 million raised across three debt programs. She also said the board maintained the quarterly cash dividend at $0.6875 per share and that operating expenses were $26.6 million, with Q4 expenses expected to rise seasonally.
Analysts focused on whether recent growth can persist into 2027 and whether Latin American credit spreads may be nearing an inflection point. Management said it was too early to give 2027 guidance, though Jorge Salas said 13%-15% still looks reasonable, and Samuel Canineu explained that growth is currently weighted toward shorter-term lending, bridge-to-bond opportunities, trade finance, and project/event-driven deals, with the bank positioned to benefit if bond-market competition eases. Questions also centered on NIM sensitivity, especially the Panama sovereign loan and the impact of prepayments; management said the Panama deal is dilutive to NIM but highly attractive on a risk-adjusted basis, and that the Q3 NIM lift included temporary prepayment-related fee acceleration. On rates, Annette said the bank runs a relatively neutral interest-rate gap and that higher rates should ultimately benefit the bank if the curve stays positive.
The call showed strong operating momentum: record portfolio size, record NII, solid fee income, and improving asset quality all came through at once. Management believes the mix of short-term lending, trade finance, and selective medium-term opportunities can keep returns attractive, while the transactional-services initiative could lower funding costs over time and deepen client relationships.
Management repeatedly warned that lending spreads remain under pressure, especially for high-quality assets, and that some of the quarter’s NIM improvement came from temporary prepayment effects that may reverse. The Panama sovereign loan will dilute reported NIM in Q4, operating expenses are expected to rise seasonally, and management said this year’s growth pace is exceptional and unlikely to repeat.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.0%
- Shares Outstanding
- 30.42M
- Float Shares
- 29.21M
of shares held by institutions
16 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BLX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Van TaylorHouse · TX03 | Sell | Mar 25, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Lsv Asset Management | 1.12M | ▼ 27.37K |
| Beddow Capital Management Inc | 294.13K | ▼ 10.73K |
| Uniplan Investment Counsel, Inc. | 150.39K | ▲ 5.14K |
| Martingale Asset Management L P | 46.13K | ▼ 1.60K |
| Ramirez Asset Management, Inc. | 42.17K | 0 |
| Rhumbline Advisers | 41.45K | ▲ 177 |
| Navellier & Associates Inc | 35.10K | ▼ 1.38K |
| Estabrook Capital Management | 20.86K | ▼ 1.67K |
| Equitable Trust Co | 20.00K | ▲ 20.00K |
| Sterling Capital Management LLC | 8.51K | ▲ 66 |
| Sbi Securities Co., Ltd. | 2.65K | ▼ 35 |
| Gamma Investing LLC | 852 | ▲ 16 |
Held by 106 ETFs
Biggest fund positions in BLX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Real Jorge Luis | buy | 2,525 |
| Oct 30, 26 | Diaz Adriana Lizzeth | buy | 1,792 |
| Aug 28, 26 | Van Hoorde Annette Marie | buy | 1,454 |
| Aug 21, 26 | Tizzoni Alejandro Horacio | buy | 1,850 |
| Jun 1, 26 | Gomes Tarciana Paula | other | 4,200 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BLX coverage
Recent articles, reports, and earnings notes.
No research on BLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLX report →